7498 Results (Page 294 of 300)
Pharmaceuticals Markets Research Reports
UK Constipation Therapeutics Market Analysis
UK Constipation Therapeutics Market was valued at $473 Mn in 2022 and is estimated to reach $673 Mn in 2030, exhibiting a CAGR of 4.5% during the forecast period. The constipation therapeutics market is experiencing growth driven by the rising prevalence of constipation worldwide, attributed to factors like aging, sedentary lifestyles, and unhealthy dietary habits, with the expanding elderly population, more prone to chronic conditions, further contributing to this market expansion. Notable participants in this industry include AbbVie, Almirall, Boehringer Ingelheim, Ferring Pharmaceuticals, Johnson & Johnson, Norgine Pharmaceuticals, Pfizer, Recordati, Sanofi, and Takeda Pharmaceuticals.
Germany Clinical Nutrition for Chronic Kidney Diseases Market Analysis
Germany Clinical Nutrition for Chronic Kidney Diseases Market was valued at $57.50 Mn in 2023 and is predicted to grow at a CAGR of 4.23% from 2023 to 2030, to $76.80 Mn by 2030. The key drivers of this industry include the high prevalence of CKD, increasing awareness and education, and technological advancements. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Canada Adult Malignant Glioma Therapeutics Market Analysis
The Canada Adult Glioma Therapeutics Market is valued at around $176 Mn in 2022 and is projected to reach $348 Mn by 2030, exhibiting a CAGR of 8.9% during the forecast period. The market is being driven by increased research and development funding, significant government investments in cancer research, owing to the increased prevalence of brain cancers, the presence of unmet healthcare needs, and a favourable regulatory environment that allows for the rapid approval of innovative medicines. Key players in the Canada Adult Malignant Glioma Therapeutics Market include Roche, Merck & Co., Pfizer, Amgen, Arbor Pharmaceuticals, Karyopharm Therapeutics, Azurity Pharmaceuticals. Medicago Inc., CogniMed Therapeutics, Inc., and others
UK Brugada Syndrome Market Analysis
The UK Brugada Syndrome Market was valued at $31.2 Mn in 2023 and is predicted to grow at a CAGR of 5.8% from 2023 to 2030, to $46.3 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, increasing awareness and diagnosis, and advancements in genetic testing. The prominent players of the UK Brugada Syndrome Market are AstraZeneca, Hikma, GlaxoSmithKline, Accord, Siemens Healthineers, Abbott, and Thermo Fisher Scientific, among others.
UAE Brain Cancer Therapeutics Market
UAE Brain Cancer Therapeutics Market valued at $12 Mn in 2022, projected to reach $28 Mn by 2030 with a 11.6% CAGR. The market for brain cancer therapeutics is expected to be driven by the anticipated rise in the incidence of brain cancer, especially glioblastoma multiforme, which would raise the demand for therapeutics. Among the prominent players in the pharmaceutical sector are Roche, Merck, Novartis, Bristol Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, Teva Pharmaceutical Industries, Sanofi, and Ipsen.
Vietnam Constipation Therapeutics Market Analysis
Vietnam Constipation Therapeutics Market was valued at $91 Mn in 2022 and is estimated to reach $153 Mn in 2030, exhibiting a CAGR of 6.73% during the forecast period. The global growth of the constipation therapeutics market is driven by factors such as aging, sedentary lifestyles, and unhealthy dietary habits. The increasing elderly population, susceptible to chronic conditions, notably contributes to this expansion. Major players in this sector comprise GlaxoSmithKline, Johnson & Johnson, Sanofi, Abbott, Bayer, AstraZeneca, Pfizer, Merck Sharp & Dohme, Boehringer Ingelheim, and United Laboratories.
UK Clinical Nutrition for Chronic Kidney Diseases Market Analysis
UK Clinical Nutrition for Chronic Kidney Diseases Market was valued at $40.80 Mn in 2023 and is predicted to grow at a CAGR of 4.03% from 2023 to 2030, to $53.80 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, technological advancements, and the growing geriatric population. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Egypt Adult Malignant Glioma Therapeutics Market Analysis
The Egypt Adult Glioma Therapeutics Market is valued at around $6 Mn in 2022 and is projected to reach $14 Mn by 2030, exhibiting a CAGR of 10.4% during the forecast period. The Egypt Adult Malignant Glioma Market is driven by factors such as increased advancements in targeted therapies, increased insurance coverage and government support and most importantly, reliance on imported drugs causing low local competitiveness and higher opportunities of growth for newer market players. Key players in the Egypt Adult Malignant Glioma Therapeutics Market include companies like Roche, Novartis, Merck & Co., Pfizer, Bristol-Myers Squibb, AbbVie, Pharco, Eva Pharma, Siemens, etc. among others
US Brain Cancer Therapeutics Market
US Brain Cancer Therapeutics Market valued at $966 Mn in 2022, projected to reach $1,869 Mn by 2030 with a 8.6% CAGR. A significant rise in the occurrence of brain cancer, specifically glioblastoma multiforme, is expected to drive the demand for treatments in the brain cancer therapeutics market. Top leading pharmaceutical companies currently operating in the industry are Roche, Novartis, Merck, Pfizer, BMS, Bayer, Celgene, AbbVie, Teva Pharmaceuticals, and Spectrum Pharmaceuticals.
China Clinical Nutrition for Chronic Kidney Diseases Market Analysis
China Clinical Nutrition for Chronic Kidney Diseases Market was valued at $126.20 Mn in 2023 and is predicted to grow at a CAGR of 7.53% from 2023 to 2030, to $209.80 Mn by 2030. The key drivers of this industry include the high prevalence of CKD, increasing awareness and education, and technological advancements. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
China Brugada Syndrome Market Analysis
The China Brugada Syndrome Market was valued at $96.5 Mn in 2023 and is predicted to grow at a CAGR of 9.3% from 2023 to 2030, to $179.8 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, increasing awareness and diagnosis, and advancements in genetic testing. The prominent players of the China Brugada Syndrome Market are AstraZeneca, Abbott, Bayer, Merck, and Sanofi, among others.
France Adult Malignant Glioma Therapeutics Market Analysis
The France Adult Glioma Therapeutics Market is valued at around $61 Mn in 2022 and is projected to reach $111 Mn by 2030, exhibiting a CAGR of 7.9% during the forecast period. The France Adult Malignant Glioma Therapeutics Market is predicted to develop gradually due to glioblastoma's poor prognosis, which drives the need for novel treatments, as well as rising incidence rates that contribute to market expansion. Key players in the France Adult Malignant Glioma Therapeutics Market include companies like Roche, Merck & Co., Novartis, Bayer, Kymab, Cellectis, Lysogene, AbbVie, Bristol-Myers Squibb, and Pfizer among others
Indonesia Clinical Nutrition for Chronic Kidney Diseases Market Analysis
Indonesia Clinical Nutrition for Chronic Kidney Diseases Market was valued at $9.40 Mn in 2023 and is predicted to grow at a CAGR of 6.03% from 2023 to 2030, to $14.20 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, technological advancements, and increasing healthcare expenditure. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Saudi Arabia Brain Cancer Therapeutics Market
Saudi Arabia Brain Cancer Therapeutics Market valued at $39 Mn in 2022, projected to reach $98 Mn by 2030 with a 12.1% CAGR. The market for brain cancer therapeutics is expected to be driven by the anticipated rise in the incidence of brain cancer, especially glioblastoma multiforme, which would raise the demand for therapeutics. The leading pharmaceutical companies presently operating in the industry are Roche, Merck, Novartis, Bristol Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, Teva Pharmaceutical Industries, Sanofi, and Ipsen.
Japan Clinical Nutrition for Chronic Kidney Diseases Market Analysis
Japan Clinical Nutrition for Chronic Kidney Diseases Market was valued at $97.60 Mn in 2023 and is predicted to grow at a CAGR of 6.53% from 2023 to 2030, to $151.90 Mn by 2030. The key drivers of this industry include the high prevalence of CKD, increasing awareness and education, and technological advancements. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Japan Brugada Syndrome Market Analysis
The Japan Brugada Syndrome Market was valued at $74.6 Mn in 2023 and is predicted to grow at a CAGR of 8.3% from 2023 to 2030, to $130.3 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, aging population, and advancements in genetic testing. The prominent players of the Japan Brugada Syndrome Market are Takeda Pharmaceuticals, Astellas, Canon Medical Systems Corporation, Terumo, Nipro, and Otsuka, among others.
Indonesia Adult Malignant Glioma Therapeutics Market Analysis
The Indonesia Adult Glioma Therapeutics Market is valued at around $13 Mn in 2022 and is projected to reach $26 Mn by 2030, exhibiting a CAGR of 8.9% during the forecast period. The UHC program of the Indonesian government, together with the nation's expanding economic might and a rise in domestic investment and research projects, is greatly boosting the manufacture of generic drugs domestically and encouraging the development of diagnostic and therapeutic technologies. Key players in the Indonesia Adult Malignant Glioma Therapeutics Market include companies like Roche, Novartis, Merck & Co., Pfizer, Bristol-Myers Squibb, Kalbe Farma, Stryker, Elekta, Siemens, etc among others
Singapore Brain Cancer Therapeutics Market
Singapore Brain Cancer Therapeutics Market valued at $3 Mn in 2022, projected to reach $6 Mn by 2030 with a 11.2% CAGR. Anticipated increases in the occurrence of brain cancer, particularly glioblastoma multiforme, are expected to substantially boost the need for treatments targeting brain cancer, thereby impacting the market's overall landscape. Currently, prominent pharmaceutical entities in the market include Merck & Co, Avatamed, Amgen, Roche, Pfizer, A*STAR, AUM Biosciences, Novartis, AstraZeneca, and Mirati Therapeutics.
Malaysia Clinical Nutrition for Chronic Kidney Diseases Market Analysis
Malaysia Clinical Nutrition for Chronic Kidney Diseases Market was valued at $2.50 Mn in 2023 and is predicted to grow at a CAGR of 6.23% from 2023 to 2030, to $3.90 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, increased awareness and education, and technological advancements. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Malaysia Brugada Syndrome Market Analysis
The Malaysia Brugada Syndrome Market was valued at $1.9 Mn in 2023 and is predicted to grow at a CAGR of 8.0% from 2023 to 2030, to $3.3 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, aging population, and increased awareness. The prominent players of the Malaysia Brugada Syndrome Market are Novartis, Amgen, GSK, Merck, Sanofi, and Medtronic, among others.
Canada Blood Disorder Therapeutics Market
Canada Blood Disorder Therapeutics Market valued at $1.072 Bn in 2022, projected to reach $1.912 Bn by 2030 with a 7.5% CAGR. The growing adoption of advanced therapies supported by government initiatives, and the rising prevalence of blood disorders, particularly among Canada's aging population, are the main factors driving the market for blood disorder treatment. The Canada Blood Disorder Therapeutics Market encompasses various players across different segments, including Takeda Pharmaceutical, Sanofi, Novo Nordisk, Pfizer, Apotex, Paladin Labs, Sandoz, Spark Therapeutics, Bluebird bio, BioMarin Pharmaceuticals etc, among various others.
Philippines Clinical Nutrition for Chronic Kidney Diseases Market Analysis
Philippines Clinical Nutrition for Chronic Kidney Diseases Market was valued at $3.50 Mn in 2023 and is predicted to grow at a CAGR of 6.53% from 2023 to 2030, to $5.40 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, increased awareness and education, and advancements in nutritional science. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Singapore Brugada Syndrome Market Analysis
The Singapore Brugada Syndrome Market was valued at $1.4 Mn in 2023 and is predicted to grow at a CAGR of 8.4% from 2023 to 2030, to $2.5 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, government fundings, and advancements in genetic testing. The prominent players of the Singapore Brugada Syndrome Market are Bayer, Roche, Siemens Healthineers, Sanofi, Thermo Fisher Scientific, and Novartis, among others.
China Blood Disorder Therapeutics Market
China Blood Disorder Therapeutics Market valued at $1.077 Bn in 2022, projected to reach $2.145 Bn by 2030 with a 9% CAGR. The key drivers of the China Blood Disorder Therapeutics Market include the growing prevalence of blood illnesses associated with an aging population and industrialization-related factors, coupled with a government push for domestic innovation, increased spending on healthcare, and rising disposable incomes. The China Blood Disorder Therapeutics Market encompasses various players across different segments, including Takeda, Roche, Bayer, Pfizer, Novartis, Johnson & Johnson, BeiGene, Innovent Biologics, Simcere, Shanghai Junshi Biosciences, etc, among various others.
Singapore Clinical Nutrition for Chronic Kidney Diseases Market Analysis
Singapore Clinical Nutrition for Chronic Kidney Diseases Market was valued at $1.90 Mn in 2023 and is predicted to grow at a CAGR of 6.63% from 2023 to 2030, to $3.00 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, increased awareness and education, and advancements in nutritional science. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.